Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

For control and trial groups A:

Inclusion Criteria:

* Patients aged 18-70 years old;
* Patients with eastern Collaborative Oncology Group (ECOG) performance status (PS) score: 0～3 points;
* International prognostic index (IPI): ≤3 points;
* Patients who were diagnosed as diffuse large B cell lymphoma (DLBCL) with initial treatment by histopathology;
* Patients with more than 1 measurable nidus (common CT or MRI scanning diameter ≥ 20 mm, and spiral CT scanning diameter ≥ 10 mm);
* Patients without dysfunction of important organs, and had normal blood routine, hepatorenal function and cardiac function. White blood cell count (WBC) ≥4.0×109/L, neutrophil count ≥1.5×109/L; platelet (PLT) count ≥100×109/L; hemoglobin (HGB) ≥95g/L; serum bilirubin (Bil) ≤1.5 folds of the upper limit of normal value, alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤2 folds of the upper limit of normal value, and serum creatinine (Scr) ≤1.5mg/dl;
* Patients with expected survival time\>3 months;
* Patients who were well informed of this study and signed the informed consent forms.
* Patients who received administration of Rituximab.

Exclusion Criteria:

* Patients who did not conform to above criteria;
* Patients who were receiving other anti-cancer therapies;
* Patients with DLBCL affected by primary breast gland, lung, testis, bone, peri-orbit, peri-spine, central nerve system and bone marrow;
* Patients with double expression, double strike, trinary expression and trinary strike and CD5+;
* Patients complicated with other non-DLBCL primary malignant tumors;
* Patients who had poor compliance with their families;
* Patients with one of the following conditions: uncontrolled metastatic nidi of central nerve system, dysfunction of important organs and severe cardiac diseases like congestive heart failure, uncontrollable arrhythmia, angina pectoris that needed long-term drug administration, valvular heart diseases, myocardial infarction and refractory hypertension, pregnancy or lactation, chronic infectious wounds, and history of uncontrollable psychological diseases.
* Patients had previous history of treatment with Cinobufacini Tablets.

For control and trial groups B

Inclusion Criteria:

* Patients aged 18-70 years old;
* Patients with eastern Collaborative Oncology Group (ECOG) performance status (PS) score: 0～3 points;
* International prognostic index (IPI): ≤3 points;
* Patients who were diagnosed as diffuse large B cell lymphoma (DLBCL) with initial treatment by histopathology;
* Patients with more than 1 measurable nidus (common CT or MRI scanning diameter ≥ 20 mm, and spiral CT scanning diameter ≥ 10 mm);
* Patients without dysfunction of important organs, and had normal blood routine, hepatorenal function and cardiac function. White blood cell count (WBC) ≥4.0×109/L, neutrophil count ≥1.5×109/L; platelet (PLT) count ≥100×109/L; hemoglobin (HGB) ≥95g/L; serum bilirubin (Bil) ≤1.5 folds of the upper limit of normal value, alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤2 folds of the upper limit of normal value, and serum creatinine (Scr) ≤1.5mg/dl;
* Patients with expected survival time\>3 months;
* Patients who were well informed of this study and signed the informed consent forms.
* Patients who did not receive administration of Rituximab.

Exclusion Criteria:

* Patients who did not conform to above criteria;
* Patients who were receiving other anti-cancer therapies;
* Patients with DLBCL affected by primary breast gland, lung, testis, bone, peri-orbit, peri-spine, central nerve system and bone marrow;
* Patients with double expression, double strike, trinary expression and trinary strike and CD5+;
* Patients complicated with other non-DLBCL primary malignant tumors;
* Patients who had poor compliance with their families;
* Patients with one of the following conditions: uncontrolled metastatic nidi of central nerve system, dysfunction of important organs and severe cardiac diseases like congestive heart failure, uncontrollable arrhythmia, angina pectoris that needed long-term drug administration, valvular heart diseases, myocardial infarction and refractory hypertension, pregnancy or lactation, chronic infectious wounds, and history of uncontrollable psychological diseases.
* Patients had previous history of treatment with Cinobufacini Tablets.